

1 **Safety and superior immunogenicity of heterologous boosting with an**  
2 **RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults**

3 Xiaoqiang Liu\*<sup>1</sup>, Yuhua Li\*<sup>2</sup>, Zhongfang Wang\*<sup>3</sup>, Shouchun Cao\*<sup>2</sup>, Weijin Huang\*<sup>2</sup>,  
4 Lin Yuan\*<sup>4</sup>, Yi-Jiao Huang<sup>5</sup>, Yan Zheng<sup>1</sup>, Jingjing Chen<sup>4</sup>, Bo Ying<sup>6</sup>, Zuoyun Xiang<sup>4</sup>,  
5 Jin Shi<sup>4</sup>, Jincun Zhao<sup>#3</sup>, Zhen Huang<sup>#4</sup>, & Cheng-Feng Qin<sup>#5,7</sup>

6 1. *Yunnan Province Centre for Disease Control and Prevention, Kunming, Yunnan,*  
7 *China.*

8 2. *National Institutes for Food and Drug Control, Beijing, China.*

9 3. *Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou,*  
10 *Guangdong, China.*

11 4. *Walvax Biotechnology Co., Ltd., Kunming, Yunnan China.*

12 5. *State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology*  
13 *and Epidemiology, Academy of Military Medical Sciences, Beijing, China.*

14 6. *Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, China.*

15 7. *Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese*  
16 *Academy of Medical Sciences, Beijing, China*

17  
18 \*These authors contributed equally: Xiaoqiang Liu, Yuhua Li, Zhongfang Wang,  
19 Shouchun Cao, Weijin Huang, Lin Yuan.

20 #Correspondence to Cheng-Feng Qin (qincf@bmi.ac.cn), Zhen Huang (hz@walvax.com),  
21 or Jincun Zhao (zhaojincun@gird.cn)

22

## 23 **Abstract**

24 Homologous and heterologous booster with COVID-19 mRNA vaccines represent the  
25 most effective strategy to prevent the ongoing Omicron pandemic. The additional  
26 protection from these prototype SARS-CoV-2 S-targeting vaccine was attributed to the  
27 increased RBD-specific memory B cells with expanded potency and breadth. Herein,  
28 we show the safety and immunogenicity of heterologous boosting with the RBD-  
29 targeting mRNA vaccine AWcorna (also term ARCoV) in Chinese adults who have  
30 received two doses inactivated vaccine. The superiority over inactivated vaccine in  
31 neutralization antibodies, as well as the safety profile, support the use of AWcorna as  
32 heterologous booster in China.

## 33 **Introduction**

34 To May 2022, the COVID-19 pandemic has claimed more than 6.28 million lives, with  
35 more than 524 million confirmed cases worldwide. The recent emergence of highly  
36 transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2  
37 (SARS-CoV-2) has triggered another major surge in both confirmed cases and deaths<sup>1</sup>.  
38 Ten COVID-19 vaccines have been approved by the World Health Organization (WHO)  
39 for emergency use, including the two mRNA vaccines, BNT162b2 and mRNA-1273,  
40 and two Chinese inactivated vaccines, CoronaVac and BBIBP-CorV. However, the  
41 rapid waning of vaccine-induced virus-neutralizing antibody titers and the continuous  
42 emergence of variants of concern (VOCs), including Alpha, Beta, Delta and Omicron,  
43 have created unprecedented challenges in the eradication of COVID-19 pandemic<sup>2-4</sup>.

44 Especially, the heavily mutated Omicron variant has been well characterized to escape  
45 from most therapeutic monoclonal antibodies, as well as sera from convalescent  
46 patients or fully vaccinated individuals<sup>5,6</sup>. Recent data has indicated that neutralizing  
47 antibody against Omicron was absent or undetectable in most Chinese populations who  
48 received two-dose inactivated vaccines<sup>7</sup>. Interestingly, preliminary data have suggested  
49 that a booster dose with mRNA vaccine BNT162b2 showed significant superiority over

50 homologous booster in titers and protection against Omicron<sup>7-9</sup>. However, the two  
51 commercial mRNA vaccines, encoding the full S protein of SARS-CoV-2, are not  
52 available in mainland China. The "made-in-China" mRNA vaccine candidate AWcorna  
53 (originally termed ARCoV), which encodes the Receptor Binding domain (RBD) of  
54 SARS-CoV-2 S protein, is being tested in the final stage of multiple-center phase III  
55 trials (<https://clinicaltrials.gov/ct2/show/NCT04847102>). It is of highly priority and  
56 urgency to provide evidence to support a better boosting strategy in mainland China for  
57 decision maker.

## 58 **Results**

59 Herein, we reported the safety and immunogenicity of a third dose of heterologous  
60 boosting with AWcorna in Chinese adults who have received two-dose inactivated  
61 vaccines. The randomized clinical trial (ChiCTR2100053701) enrolled 300 adults  
62 (ages $\geq$ 18 years). All eligible subjects received 2-dose priming vaccination with the  
63 inactivated vaccine, CoronaVac or BBIBP-CorV. At about 6-month post-priming, all  
64 subjects were randomly assigned to either the AWcorna (n=200; heterologous) or  
65 CoronaVac (n=100; homologous) booster group (Supplementary information, **Fig.**  
66 **S1a**). In the AWcorna group, the median age was 43.0 years (Interquartile rate, IQR:  
67 36.5-49.0), and the CoronaVac group was 40.0 years (IQR: 34.0-48.5) ( $P=0.5165$ )  
68 (Supplementary information, **Table S1**). There were 116 (58%) and 55 (55%) male  
69 participants in the AWcorna and CoronaVac groups, respectively ( $P=0.6208$ ).  
70 Meanwhile, no significant differences were observed in the Body Mass Index (BMI),  
71 vital signs, and comorbid condition between the two groups at the baseline (All  $P>0.05$ ).  
72 All subjects completed the enrollment vaccination and three blood examinations  
73 consecutively at pre-booster or 0 days,  $14\pm 2$  days, and  $28\pm 2$  days post-booster  
74 vaccination. Subsequently, the neutralization and IgG antibody titers against wild-type  
75 (WT) SARS-CoV-2 and VOCs were assessed at pre-booster, 14- and 28-day post-  
76 booster by the standard cytopathic effect (CPE) based assay and ELISA, respectively

77 (Supplementary information, Methods). The WHO standard IgG antibody (NIBSC  
78 code 20/136) was used as a reference sample for all serological assays.

79 As expected, the live virus neutralization titers against WT SARS-CoV-2 were below  
80 the detection limit before boosting in all participants from both groups (**Fig. 1a**).  
81 Remarkably, AWcorna booster induced a 66.59-fold increase against WT SARS-CoV-  
82 2, and the geometric mean titers (GMTs) reached 293.9 and 242.4 at 14 and 28 days  
83 post booster, respectively (WHO Reference cut-off 1:139), while the GMTs in  
84 CoronaVac booster groups was only 89.1 and 64.3, respectively (**Fig. 1a** and  
85 supplementary information, **Table S2**). Similarly, the neutralization antibody titers  
86 against the Delta variant also increased significantly after the third dose booster either  
87 with AWcorna and CoronaVac, while the GMTs in Awcorna groups were 5.1- and 6.5-  
88 fold higher than that in CoronaVac group at 14 and 28 days post booster (**Fig. 1b** and  
89 supplementary information, **Table S2**). In addition, the increasing trends are similar in  
90 both 18-59 and  $\geq 60$  years old participants (Supplementary information, **Fig. S2a,b**).

91 Despite the neutralization antibody titers against the Omicron variant showed  
92 significant reduction in comparison with that against the WT virus in both groups, the  
93 GMTs against Omicron maintained 28.1 at 28-day after AWcorna booster, while the  
94 GMT in the CoronaVac booster group was only 6.4 (**Fig. 2a** and supplementary  
95 information, **Table S2**). Most importantly, 83.75% of participants in the AWcorna  
96 booster group achieved the 1:8 threshold of neutralization antibody titers against the  
97 Omicron relative to that of only 35% of participants in the CoronaVac booster group  
98 (**Fig. 2b**; 95% Confidence Interval, CI: 30.82-63.84;  $P < 0.0001$ ).

99 Moreover, the RBD-specific IgG antibodies titers also showed a sharp increasement in  
100 both booster groups, and the GMT in AWcorna booster group was 6.8- and 7.1- fold  
101 higher than that in the CoronaVac booster group at both 14-day and 28-day time points,  
102 respectively (all  $P < 0.0001$ ) (**Fig. 3a** and supplementary information, **Table S3**). Taken  
103 together, these results demonstrate that heterologous boosting with AWcorna induces

104 higher neutralization and IgG antibodies against WT, Delta and Omicron variants than  
105 homologous booster.

106 Additionally, we observed the safety profile of the booster dose of AWcorna. Solicited  
107 local and systemic adverse events (AEs) were recorded within 30 mins and in a window  
108 of 0-14 days, and unsolicited AEs were documented within 0-28 days post-booster  
109 vaccination (Supplementary information, **Table S4**). For both vaccines, pain at the  
110 injection site is the most reported local AE (incidence rate, IR:17% in AWcorna vs. 2%  
111 in CoronaVac;  $P<0.0001$ ), mostly at the Grade 1 level (**Fig. 4a**). Fever was the most  
112 common systemic AE (IR: 33.5%), followed by headache (IR: 26.0%) and muscle  
113 aches (IR: 7.5%) in AWcorna group (**Fig. 4b**). A total of 8 subjects reported grade 3  
114 fever (IR:4%) among the 200 participants in AWcorna group. For the CoronaVac group,  
115 headache represented as the most frequent systemic AE (IR: 7.0%), followed by fever  
116 (IR: 4.0%). No serious adverse events (SAE) were reported in both groups.

## 117 **Discussion**

118 Collectively, our present study clearly demonstrated that a 3<sup>rd</sup> dose of heterologous  
119 boosting with AWcorna was safe and potential protective against the circulating Delta  
120 and Omicron variants. Compared with phase 1 trial, the total IRs of local and systemic  
121 AEs for AWcorna booster showed significant improvement<sup>10</sup>, especially the IR of grade  
122 3 fever reduced to 4% (Supplementary information, **Table S4**), which was comparable  
123 to the other two approved mRNA vaccines<sup>11</sup>. The phase 1 trial of AWcorna only  
124 included 20 adults aged 18-59 (15 µg group), while our present cohort enrolled 200  
125 participants, including 10 subjects aged over 60. The expansion of sample size and  
126 improvement in vaccine manufacturing technologies contributed to the improved safety  
127 profile observed in our present study. The ongoing international phase 3 trials with  
128 28,000 participants will provide more meaningful data about the safety profile of  
129 AWcorna.

130 Previously, we have demonstrated that homologous boosting with AWcorna readily  
131 induced high neutralization antibodies against WT and Omicron variant in mice<sup>12</sup>, our  
132 present data in human further supported heterologous booster with this China-made  
133 mRNA vaccine AWcorna in Chinese populations. Many cities in China are under the  
134 attack of Delta and Omicron variants, while few or no neutralization antibodies against  
135 Omicron was detected in most Chinese populations<sup>7,13</sup>, a third dose of booster has been  
136 recommended by the WHO and National Health Commission of China. Of all COVID-  
137 19 vaccines generated from different technology platform, mRNA vaccine represents  
138 as the most reasonable choice as either homologous or heterologous booster. The  
139 neutralization titers against Delta and Omicron variants in AWcorna booster group were  
140 6.5-fold and 4.4-fold higher than that in CoronaVac booster group, respectively (**Fig.**  
141 **1b, c**), and the AWcorna booster induced the seroconversion of Omicron neutralization  
142 in over 83% individuals (**Fig. 1d**). A third dose of S-targeting mRNA vaccine was  
143 evidenced to increase the number of RBD-specific memory B cells with expanded  
144 potency and breadth, thus contributing to the additional protection against VOCs  
145 including Omicron<sup>14,15</sup>, highlighting the rationale of RBD-targeting mRNA vaccine as  
146 booster. Given that more and more Chinese population have received three-dose  
147 inactivated vaccines, additional clinical trials are being conducted to assay the benefits  
148 of heterologous boosting with AWcorna.

149 Finally, despite the vaccine effectiveness of AWcorna booster in preventing infection  
150 by SARS-CoV-2 and other VOCs remains to be determined, the induction of potent  
151 neutralization antibodies against WT and VOCs, as well as the affordable safety profile,  
152 support the emergency use of AWcorna as heterologous booster in China. A more  
153 potent mRNA vaccine and improved booster strategy should be warranted to meet the  
154 urgent and huge need to stop the ongoing Omicron outbreaks in China and COVID-19  
155 pandemic worldwide.

## 156 **METHODS AND MATERIALS**

### 157 **Study design**

158 We conducted a randomized clinical trial involving 300 adults ( $\geq 18$  years of age) who  
159 were tested negative by RT-PCR screening for COVID-19 at the time of participation  
160 to elucidate the immunogenicity and safety of an mRNA-based vaccine (AWcorn) as  
161 a booster compared to that of homologous booster using an inactivated viral vaccine  
162 (CoronaVac).

### 163 **Ethics statement**

164 The trial was reviewed and approved by the Research Ethics Committee of the Center  
165 for Disease Control and Prevention of Yunnan province. The study protocol and related  
166 materials were approved by the independent Ethics Committees as well, and this trial  
167 was conducted in accordance with the Declaration of Helsinki and Good Clinical  
168 Practice with the register number of ChiCTR2100053701 (NO. 2021-15). Written  
169 informed consents were obtained from each participant before the screening.

### 170 **Participants**

171 Eligible participants met all inclusion criteria and did not trigger any exclusion criteria.  
172 Those aged 18 years and above, received full 2-dose inactivated viral priming around  
173 6 months ago. Of the 300 participants, 175 received 2-dose CoronaVac, 14 received 2-  
174 dose BBIBP CorV, and 111 received one-dose CoronaVac and 1-dose BBIBP CorV.  
175 Participants with a previous clinical or virologic COVID-19 diagnosis or SARS-CoV-  
176 2 infection or women with positive urine pregnancy test results were excluded from this  
177 study. Participants with a medical history of convulsion, serious acute hypersensitive  
178 reaction to vaccines, acute febrile diseases or infectious diseases, congenital or acquired  
179 angioedema, asplenia or functional asplenia, thrombocytopenia or other coagulation  
180 disorders, anti-allergy therapy, or blood products within 3 months were also excluded.

### 181 **Randomization**

182 Each participant was assigned a unique subject ID by authorized assigners successively  
183 according to a Prespecified allocation kit, which was generated by an independent

184 randomization statistician from Beijing Key Tech Statistical Consulting Co., Ltd. via  
185 SAS software (SAS® Institute, Cary, North Carolina, USA) with the ratio of 2:1 to the  
186 AWcorna and CoronaVac groups. Since the different appearances of the two kinds of  
187 vaccines, inoculators could not keep in blind when vaccines had been used. And hence,  
188 staff who were assigned to inoculate would not be involved in any other research jobs,  
189 especially for subjects' safety follow-up procedures. Participants would be masked  
190 when receiving the jab by a special curtain in the injection room to avoid the  
191 identification of he or she, and disclosure of the allocated group. Other investigators,  
192 laboratory staff, and outcome assessors were kept blinded also.

### 193 **Interventions**

194 The AWcorna vaccine (15 µg/dose) (batch number RR202109006) is manufactured by  
195 Yuxi Walvax Biotechnology Co. Ltd. (an affiliate of Walvax Biotechnology Co., Ltd.),  
196 and supplied in pre-filled 0.5 ml syringes. The CoronaVac (Sinovac) vaccine, is an  
197 inactivated whole-virion vaccine with aluminum hydroxide as the adjuvant. Each dose  
198 of CoronaVac contains 3 µg SARS CoV-2 virion in a 0.5 ml aqueous suspension for  
199 injection with 0.45 mg/ml aluminum.

### 200 **Assessments**

201 After injection, subjects received an in-site 30-minutes safety observation conducted  
202 by research staff to confirm if any immediate reactions occurred. Any adverse events  
203 (AEs) discovered or any relevant concomitant medications declared within 28 days  
204 after vaccination were recorded by subjects with the help of the daily cards and  
205 connections cards which were prepared and managed by the study team. For each  
206 subject, serious adverse events (SAEs), adverse events of interest (AESI), and  
207 pregnancy were collected from the enrollment till 12 months after his/her booster dose.  
208 Up to 6 ml of blood sample was collected from each participant at baseline pre-booster  
209 vaccination and on day 14 and day 28 after receiving the booster dose.

## 210 **Endpoints**

211 The primary endpoints for safety were: 1) The incidence rates of adverse  
212 reactions/adverse events within 30 minutes, during Day 0-14 and Day 0-28 after  
213 vaccination; and 2) The incidence rates of adverse reactions/adverse events with a  
214 severity of grade 3 and above within 30 minutes and during Day 0-14 and Day 0-28  
215 after vaccination. The primary immunogenicity endpoint was the titers of neutralizing  
216 antibody against wild type SARS-CoV-2 as measured by live virus neutralization assay  
217 14 days post booster.

## 218 **Laboratory assays**

219 The neutralizing antibodies in sera against the wild-type strain (GenBank: MT123291),  
220 Delta variant (IQTC-IM2175251), and Omicron variant (IQTC-Y216017) (Guangzhou  
221 Customs Technology Center, Guangzhou, China) were determined by using a  
222 cytopathic effect (CPE)-based microneutralization assay. Two-fold serial dilutions  
223 (starting from 1:4) of heat-inactivated sera were tested in duplicate wells for the  
224 presence of neutralizing antibodies in the monolayer of Vero E6 cells. 100 TCID<sub>50</sub> of  
225 virus in 50 µl/well was incubated with 50 µl of serum in 96-well plates for 2 h. Vero  
226 E6 cells were trypsinized and resuspended in Dulbecco's Modified Eagle Medium  
227 (DMEM) containing 4% of fetal bovine serum and 1% of pen/strep at a concentration  
228 of  $1.2 \times 10^5$  cells/ml and 100 µl of cells suspension were then added into the 96-well  
229 plates, followed by incubation at 37 °C, 5% CO<sub>2</sub> for 4 days. The neutralization was  
230 determined by the appearance of CPE in images captured with Celigo Image Cytometer  
231 on day 4 post-infection. The neutralizing antibody titer was defined as the reciprocal of  
232 the highest sample dilution that protected at least 50% of cells from CPE.

233 RBD-specific ELISA antibody responses were measured using an indirect ELISA assay  
234 with a cutoff titer of 1:10. The commercial Anti-SARS-CoV-2 RBD IgG ELISA kit  
235 was used for detection. Measurement was performed using a Multiskan GO reader

236 (Thermo Fisher) to detect optical density at 450 and 630 nm using SkanIt Software for  
237 Microplate Readers (version 4.1.0.43).

238 The WHO international standard for anti-SARS-CoV-2 IgG (NIBSC code 20/136) was  
239 used as a reference with the serum samples measured in this study for calibration of the  
240 serological assays. The WHO reference (NIBSC code: 20/136) is equivalent to a live  
241 viral neutralizing antibody titer of 1:139 against wild-type SARS-CoV-2 and a titer of  
242 1:213 against the Delta variant B.1.617.2, while the WHO reference (1,000 BAU/ml in  
243 serum) is equivalent to an RBD-specific IgG ELISA antibody titer of 1:5,490. Live  
244 viral neutralizing antibodies against wild-type strain and the Delta variant and levels of  
245 RBD-binding IgG isotypes in serum were measured on days 0, 14, and 28 after the  
246 booster. Live viral neutralizing antibodies against the Omicron variant BA.1.1 were  
247 detected only on day 28 after the booster in a subgroup randomly selected from both  
248 groups.

#### 249 **Sample size**

250 The sample size was determined based on the hypothesis that the booster vaccination  
251 of mRNA vaccine following the two-dose inactivated vaccine regimen be non-inferior  
252 to that of the booster of inactivated vaccine in neutralizing antibody. It was assumed  
253 that the pooled standard deviation of  $\log_{10}$ -transformed neutralizing data was 0.5 and  
254 equal GMT in both the mRNA vaccine group and CoronaVac group. 200 participants  
255 in the mRNA group and 100 participants in the CoronaVac group could have at least  
256 80% power to observe that the lower limit of the 95% confidence interval of GMT ratio  
257 between the two groups was greater than the non-inferiority margin (2/3), with the one-  
258 sided significance level of 2.5%.

#### 259 **Statistical analysis**

260 The geometric mean titer (GMT) and 95% confidence interval (CI) were used to  
261 describe neutralizing results in the mRNA vaccine group and CoronaVac group after

262 booster vaccination, and the GMT ratio between the two groups and 95% CI were  
263 estimated. The non-inferiority result would be concluded if the lower bound of 95%CI  
264 was larger than 2/3. When the non-inferiority conclusion was concluded, the superiority  
265 would be considered sequentially if the lower bound was larger than 1. The  
266 seroconversion rate and Clopper-Pearson 95%CI after booster vaccination were  
267 estimated as well, and the difference between the two groups was calculated using the  
268 Miettinen-Nurminen method.

269 We assessed the number and proportion of participants with adverse reactions 0-28 days  
270 after the booster dose. For fever, besides the NMPA standard, we also derived the oral  
271 temperature by adding 0.2°C to the collected auxiliary temperature, and then re-graded  
272 the adverse reaction based on the FDA standard to provide more comparable results  
273 with marketed vaccines. We used the  $\chi^2$  test or Fisher's exact test to analyze categorical  
274 data, the t-test to analyze the log-transformed antibody titers, and the Wilcoxon rank-  
275 sum test for data not following a normal distribution. The correlation between  
276 concentrations of log-transformed neutralizing antibody and binding antibody levels  
277 was analyzed using Pearson's correlation. The primary analysis was performed based  
278 on the per-protocol population. Statistical analyses were performed using SAS (version  
279 9.4).

## 280 **ACKNOWLEDGMENTS**

281 We thank all the participants in this trial and all staff in the research sites at Lancang  
282 CDC and Yunnan CDC. The authors acknowledge members from the Guangzhou  
283 Institute of Respiratory Health, Guangzhou Customs Technology Center, the Vazyme  
284 Medical Technology, the Beijing Key Tech Statistical Consulting, and the Beijing Stem  
285 Technology for technical support and collaboration. We sincerely thank Prof. Xuanyi  
286 Wang and Prof. Haifeng Li for critical reading and insightful suggestion for this  
287 manuscript. This work was supported in part by grant from the National Key Research  
288 and Development Program of China (2021YFC2302400) and the National Science  
289 Foundation of China (82151222). C.-F.Q. was supported by the National Science Fund

290 for Distinguished Young Scholars (81925025), the Innovative Research Group  
291 (81621005) from the National Science Foundation of China and the Innovation Fund  
292 for Medical Sciences (2019-I2M-5-049) from the Chinese Academy of Medical  
293 Science.

#### 294 **AUTHOR CONTRIBUTIONS**

295 J.Z., Z.H. and C.-F.Q. conceived and supervised the project. X.L., J.Z., Z.W. and L.Y.  
296 designed and coordinated the experiments. J.Z. and Z.W. performed the laboratory  
297 assays. Y.L., W.H., and S.C. completed the quality assurance of this product and  
298 provided essential guidance on laboratory assays. J.S. and B.Y. provided technical  
299 expertise on mRNA vaccine production. Y.Z. and J.C. analyzed the data. L.Y., J.C., Y.-  
300 J.H., Z.X. and C.-F.Q. drafted the manuscript. All authors revised and approved the  
301 final version.


#### 302 **COMPETING INTERESTS**

303 This trial was sponsored by the Walvax Biotechnology. AWcornia was co-developed by  
304 AMMS, Abogen, and Walvax. C.-F. Q. and B.Y. are co-inventor of AWcornia. Z.H.,  
305 L.Y., J.C., Z.X. and J.S. are employees of Walvax. B. Y. is the founder of Abogen. The  
306 other authors declare no conflicts of interest.

#### 307 **REFERENCES**

- 308 1 Cao, Y. *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing  
309 antibodies. *Nature* **602**, 657-663, doi:10.1038/s41586-021-04385-3 (2022).
- 310 2 Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine  
311 over 6 Months. *The New England journal of medicine* **385**, e84,  
312 doi:10.1056/NEJMoa2114583 (2021).
- 313 3 Cao, Y. *et al.* Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001  
314 booster after two doses of inactivated vaccine. *Cell Res* **32**, 107-109,  
315 doi:10.1038/s41422-021-00596-5 (2022).
- 316 4 Ai, J. *et al.* Recombinant protein subunit vaccine booster following two-dose  
317 inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers  
318 against SARS-CoV-2 and Variants of Concern. *Cell Res* **32**, 103-106,  
319 doi:10.1038/s41422-021-00590-x (2022).

- 320 5 Planas, D. *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody  
321 neutralization. *Nature* **602**, 671-675, doi:10.1038/s41586-021-04389-z (2022).
- 322 6 Wang, K. *et al.* Memory B cell repertoire from triple vaccinees against diverse SARS-  
323 CoV-2 variants. *Nature* **603**, 919-925, doi:10.1038/s41586-022-04466-x (2022).
- 324 7 Cheng, S. M. S. *et al.* Neutralizing antibodies against the SARS-CoV-2 Omicron variant  
325 BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.  
326 *Nat Med* **28**, 486-489, doi:10.1038/s41591-022-01704-7 (2022).
- 327 8 Mok, C. K. P. *et al.* Comparison of the immunogenicity of BNT162b2 and CoronaVac  
328 COVID-19 vaccines in Hong Kong. *Respirology* **27**, 301-310, doi:10.1111/resp.14191  
329 (2022).
- 330 9 Jara, A. *et al.* Effectiveness of homologous and heterologous booster doses for an  
331 inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. *Lancet Glob  
332 Health*, doi:10.1016/S2214-109X(22)00112-7 (2022).
- 333 10 Chen, G. L. *et al.* Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine  
334 in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. *The  
335 Lancet. Microbe* **3**, e193-e202, doi:10.1016/s2666-5247(21)00280-9 (2022).
- 336 11 Munro, A. P. S. *et al.* Safety and immunogenicity of seven COVID-19 vaccines as a third  
337 dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-  
338 BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* **398**,  
339 2258-2276, doi:10.1016/S0140-6736(21)02717-3 (2021).
- 340 12 Zhang, N. N. *et al.* Rapid development of an updated mRNA vaccine against the SARS-  
341 CoV-2 Omicron variant. *Cell Res*, doi:10.1038/s41422-022-00626-w (2022).
- 342 13 Zhang, R. *et al.* A protein subunit vaccine booster following two doses of inactivated  
343 SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in  
344 mice. *Lancet Microbe* **3**, e165-e166, doi:10.1016/S2666-5247(21)00331-1 (2022).
- 345 14 Muecksch, F. *et al.* Increased Memory B Cell Potency and Breadth After a SARS-CoV-2  
346 mRNA Boost. *Nature*, doi:10.1038/s41586-022-04778-y (2022).
- 347 15 Goel, R. R. *et al.* Efficient recall of Omicron-reactive B cell memory after a third dose  
348 of SARS-CoV-2 mRNA vaccine. *Cell*, doi:10.1016/j.cell.2022.04.009 (2022).
- 349
- 350




351

352 **Fig.1 GMT of neutralizing antibodies to live wild-type SARS-CoV-2 or Delta**  
 353 **variant.**

354 **a** Geometric mean titer (GMT) of neutralizing antibodies to live wild-type (WT) SARS-  
 355 CoV-2. The WHO reference serum (1,000 IU/ml) was equivalent to a live viral  
 356 neutralizing antibody titer of 1:139 against WT. **b** GMT of neutralizing antibodies to  
 357 the Delta variant. The WHO reference was 1:213 against the Delta variant (the dash  
 358 line in red). Eligible participants primed with 2-doses of inactivated vaccine were  
 359 randomly allocated to AWcornia group (n=200) and CoronaVac group (n=100) to  
 360 receive a booster dose respectively. GMT data are presented in box-and-whisker plots.  
 361 The figures above error bars indicate the percentage. *P* values were obtained from  
 362 comparisons between the two treatment groups using *t*-tests for log-transformed  
 363 antibody or two-sided  $\chi^2$  tests for categorical data.

364




365

366 **Fig.2 GMT of neutralizing antibodies to Omicron variant.**

367 **a** GMT of neutralizing antibodies to the Omicron variant was measured in the subgroup  
368 (120 participants with the first 120 subject numbers, 80 from AWcorna and 40 from  
369 CoronaVac group). Sera were measured 28 days after booster only, thus no baseline  
370 analysis was performed. **b** Seropositive rates (%) of neutralizing antibody to the  
371 Omicron variant. GMT data are presented in box-and-whisker plots. The figures above  
372 error bars indicate the percentage. *P* values were obtained from comparisons between  
373 the two treatment groups using *t*-tests for log-transformed antibody or two-sided  $\chi^2$   
374 tests for categorical data.

375

376 a




377

378 **Fig.3 GMT of anti-RBD IgG antibodies to WT SARS-CoV-2.**

379 **a** GMTs of anti-RBD IgG antibodies to WT SARS-CoV-2. The WHO reference (1,000  
380 binding antibody unit (BAU)/ml in serum) is equivalent to an RBD-specific IgG ELISA  
381 antibody titer of 1:5490. The cutoff value for the response was 1:8 for live virus  
382 neutralizing antibody and 1:10 for anti-RBD IgG. GMT data are presented in box-and-  
383 whisker plots. The figures above error bars indicate the percentage. *P* values were  
384 obtained from comparisons between the two treatment groups using *t*-tests for log-  
385 transformed antibody or two-sided  $\chi^2$  tests for categorical data.

386



387

388


389 **Fig.4 Safety of Heterologous boosting with AWcorna in Chinese adults.**

390 **a** The percentage of participants with local adverse events (AEs). **b** The percentage of  
 391 participants with systemic AEs. These AEs were monitored in the 14 days window after  
 392 the administration of the booster.

393

394

395



396

397


398 **Fig. S1 Consolidated standards of reporting trials (CONSORT) flow diagram**

399 **a** Between the trial screening and randomization, 29 volunteers were excluded. All of them  
400 triggered the exclusion criteria. A total of 300 eligible subjects, who had received 2 doses of  
401 inactivated vaccine about 6 months ago, were randomly assigned to either the AWcornia (n=200;  
402 heterologous) or CoronaVac (n=100; homologous) booster group. All the randomized  
403 participants received vaccines at their free will and received all the scheduled follow-ups.

404

405

406



407

408 **Fig.S2 Cross neutralization against WT and Delta viruses in different age groups.**

409 **a,b** GMT of neutralizing antibodies to wild-type SARS-CoV-2 and Delta variant for younger  
 410 adult population aged 18-59 (AWcornia=190, CoronaVac=90) (a) and elder population aged 60  
 411 and above (AWcornia=10, CoronaVac=6) (b). GMT data are presented in box-and-whisker  
 412 plots. The whiskers indicate the range, the top and bottom of the boxes indicate the interquartile  
 413 range, and the horizontal line within each box indicates the median. Figures with the x suffix  
 414 indicate the GMT ratio between groups or GMT increase fold raised from pre- to post-booster  
 415 level. *P* values were obtained from comparisons between the two treatment groups using *t*-tests  
 416 for log-transformed antibody.

417

418 **Table S1. Baseline characteristics of the trial participants, who had received two doses of**  
 419 **priming inactivated vaccine. \***

	<b>AWcorna</b>	<b>CoronaVac</b>	<b>P-Value</b>
	<b>(N=200)</b>	<b>(N=100)</b>	
<b>Age(Median, IQR)</b>	43.0 (36.5,49.0)	40.0 (34.0,48.5)	0.5165
<b>Sex, male(%)</b>	116 (58.00)	55 (55.00)	0.6208
<b>BMI(min-max) †</b>	23.56 (15.58-34.53)	23.22 (18.31-33.31)	0.3998
<b>Ethnicity‡</b>			
Lahu, n(%)	179 (89.50)	88 (88.00)	0.5418
Wa, n(%)	1 (0.50)	0 (0.00)	
Hani, n(%)	10 (5.00)	3 (3.00)	
Yi, n(%)	2 (1.00)	1 (1.00)	
Dai, n(%)	0 (0.00)	0 (0.00)	
Other, n(%)	8 (4.00)	8 (8.00)	
<b>RT-PCR, negative(%)</b>	200(100)	100(100)	1.0000
<b>Vital Signs</b>			
Systolic Pressure	118(81-141)	118(85-140)	0.9615
Diastolic Pressure	73(48- 89)	74(56-90)	0.3679
Pulse	79(56-114)	81(53-110)	0.2182
<b>Comorbidities</b>			
<b>Any (%)</b>	9	9	1.0000
Gastrointestinal disorders (%)	3.5	2	0.7227
Vascular disorders (%)	1	2	0.6030
Respiratory, thoracic and mediastinal disorders (%)	1.5	0	0.5533
Infections and infestations (%)	1	1	1.0000
Musculoskeletal and connective tissue disorders (%)	0.5	1	1.0000
Nervous system disorders (%)	0.5	1	1.0000
Blood and lymphatic system disorders (%)	1	0	0.5541
Endocrine disorders (%)	0	1	0.3333
Investigations (%)	0.5	0	1.0000
Reproductive system and breast disorders (%)	0	1	0.3333
<b>SARS-CoV-2 specific antibody titers on day 0§</b>			
Geometric Mean Titer of anti-RBD IgG (Mean, 95%CI)	134.7	140.8	0.7061

	(118.3, 153.4)	(115.3, 172.0)	
Geometric Mean Titer of nAb against Wild-Type SARS-CoV-2 (Mean, 95% CI)			
	4.4(4.2, 4.7)	4.5(4.2, 4.9)	0.7831
Geometric Mean Titer of nAb against Delta Variant (Mean, 95% CI)			
	4.2(4.0, 4.4)	4.1(4.0, 4.3)	0.5951

---

420 \* The first trial visit occurred before the booster, and the second and third trial visit occurred 14- and 28-days after  
421 administration of the booster. IQR denotes interquartile range.

422 † The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.

423 ‡ Categories were reported by the participants. The categories shown are those used by the investigators to denote  
424 ethnicity.

425 § In the two groups, blood was drawn on day 0, which was the day of the first trial visit. Day 0 was also the day of  
426 the booster in the two groups.

427

428 **Table S2. Neutralizing antibodies to the wild-type SARS-CoV-2 as well as Delta and Omicron variants before and after booster.**

	<b>AWcornia</b>	<b>CoronaVac</b>	<b>GMT/GMI Ratio (AWcornia /CoronaVac)</b>	<b>Statistics</b>	<b>P value</b>
	<b>N=200</b>	<b>N=100</b>	<b>or Diff. in % (AWcornia -CoronaVac)</b>		
<b>Wild-Type</b>					
Pre-Booster					
GMT	4.4(4.2, 4.7)	4.5(4.2, 4.9)	NA	$t=-0.275$	0.7831
Seropositive* (%)	9.00(5.42, 13.85)	10.00(4.90, 17.62)	NA	$\chi^2=0.079$	0.7790
D14					
GMT	293.9(260.4, 331.7)	89.1(73.7, 107.8)	3.3(2.7, 4.1)	NA	<0.0001
GMI	66.2(58.3, 75.1)	19.8(16.3, 24.0)	3.3(2.7, 4.2)	NA	<0.0001
Seroconversion* (%)	99.00(96.43, 99.88)	98.00(92.96, 99.76)	1.00(-1.92, 6.08)	NA	0.6030
4-Fold Increase (%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433
D28					
GMT	242.4(216.4, 271.4)	64.3(53.6, 77.2)	3.8(3.1, 4.6)	NA	<0.0001
GMI	54.6(48.4, 61.6)	14.3(11.9, 17.1)	3.8(3.1, 4.7)	NA	<0.0001
Seroconversion** (%)	99.50(97.25, 99.99)	98.00(92.96, 99.76)	1.50(-1.08, 6.55)	NA	0.2585
4-Fold Increase (%)	99.00(96.43, 99.88)	94.00(87.40, 97.77)	5.00(1.11, 11.57)	NA	0.0183
<b>Delta</b>					
Pre-Booster					
GMT	4.2(4.0, 4.4)	4.1(4.0, 4.3)	NA	$t=0.532$	0.5951

Seropositive* (%)	3.00(1.11, 6.42)	3.00(0.62, 8.52)	NA	NA	1.0000
<b>D14</b>					
GMT	286.8(252.9, 325.3)	56.5(45.6, 70.0)	5.1(4.0, 6.4)	NA	<0.0001
GMI	68.5(60.1, 78.0)	13.7(11.1, 17.0)	5.0(3.9, 6.3)	NA	<0.0001
Seroconversion	99.00(96.43, 99.88)	96.00(90.07, 98.90)	3.00(-0.38, 8.93)	NA	0.0979
4-Fold Increase (%)	99.00(96.43, 99.88)	91.00(83.60, 95.80)	8.00(3.35, 15.32)	NA	0.0011
<b>D28</b>					
GMT	257.8(225.7, 294.5)	39.8(32.1, 49.3)	6.5(5.1, 8.2)	NA	<0.0001
GMI	61.5(53.7, 70.5)	9.7(7.8, 11.9)	6.4(5.0, 8.1)	NA	<0.0001
Seroconversion* (%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433
4-Fold Increase (%)	99.00(96.43, 99.88)	81.00(71.93, 88.16)	18.00(11.27, 26.87)	NA	<0.0001
<b>Omicron (For Subgroup)</b>	<b>N=80</b>	<b>N=40</b>			
<b>D28</b>					
GMT	28.1(21.4, 36.8)	6.4(5.0, 8.3)	4.4(2.9, 6.7)	NA	<0.0001
Seropositive* (%)	83.75(73.82, 91.05)	35.00(20.63, 51.68)	48.75(30.82, 63.84)	NA	<0.0001

429 The geometric mean of titer (GMT) and geometric mean of increase against the pre-booster level (GMI) are presented with corresponding 2-sided 95%  
430 confidence interval (CI) respectively in AWcorna and CoronaVac groups, and the ratios of GMT or GMI between the two groups and corresponding 95% CI  
431 are accordingly showed.

432 The non-inferiority result would be concluded if the lower bound of 95% CI of the ratio between groups (AWcorna/CoronaVac) is larger than 2/3 When the  
433 non-inferiority conclusion is concluded, the superiority would be considered sequentially if the lower bound was larger than 1.

434 The seroconversion rate and the 4-fold Increase rate with their corresponding Clopper-Pearson 95% CI are shown, and the difference between the two groups  
435 were calculated using Miettinen-Nurminen method.

436 N=the number of participants included the per-protocol population. The p values are the results of comparison between the AWcorna and CoronaVac groups.  
437

438 \*Seropositive defined as the status that the nAb level of a subject achieved the threshold of 1:8 (Limit of Detection, LOD).

439 \*\*Seroconversion due to booster dose at a subject level is defined as a change from below the LOD to equal or above LOD, or for those who above the LOD  
440 pre-booster experienced at least a 4-fold rise in terms of nAbs.

441

442 **Table S3. RBD-Specific antibodies before and after booster.**

	<b>AWcornia</b>	<b>CoronaVac</b>	<b>GMT/GMI Ratio (AWcornia /CoronaVac)</b>	<b>Statistics</b>	<b>P value</b>
	<b>N=200</b>	<b>N=100</b>	<b>or Diff. in % (AWcornia -CoronaVac)</b>		
<b>Pre-Booster</b>					
GMT	134.7(118.3, 153.4)	140.8(115.3, 172.0)	NA	<i>t</i> =-0.378	0.7061
Seropositive* (%)	100.00(98.17, 100.00)	100.00(96.38, 100.00)	NA	NA	1.0000
<b>D14</b>					
GMT	29270.4(26074.5, 32858.1)	4317.8(3680.1, 5065.9)	6.8 (5.6, 8.3)	NA	<0.0001
GMI	217.3(184.9, 255.3)	30.7(25.5, 36.9)	7.1 (5.5, 9.2)	NA	<0.0001
Seroconversion* (%)	99.50(97.25, 99.99)	98.00(92.96, 99.76)	1.50(-1.08, 6.55)	NA	0.2585
4-Fold Increase(%)	99.50(97.25, 99.99)	98.00(92.96, 99.76)	1.50(-1.08, 6.55)	NA	0.2585
<b>D28</b>					
GMT	21874.4(19568.4, 24452.3)	3102.3(2661.8, 3615.8)	7.1 (5.8, 8.5)	NA	<0.0001
GMI	162.4(138.0, 191.1)	22.0(18.4, 26.4)	7.4 (5.7, 9.6)	NA	<0.0001
Seroconversion* (%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433
4-Fold Increase(%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433

443 The geometric mean of titer (GMT) and geometric mean of increase against the pre-booster level (GMI) are presented with corresponding 2-sided 95%  
 444 confidence interval (CI) respectively in AWcornia and CoronaVac groups, and the ratios of GMT or GMI between the two groups and corresponding 95% CI  
 445 are accordingly showed.

446 The seroconversion rate and the 4-fold Increase rate with their corresponding Clopper-Pearson 95% CI are shown, and the difference between the two groups  
447 were calculated using Miettinen-Nurminen method.

448 N=the number of subjects included the per-protocol population. The p values are the results of comparison between the AWcornia and CoronaVac groups.

449 \*Seropositive defined as the status that the nAb level of a subject achieved the threshold of 1:10 (Limit of Detection, LOD).

450 \*\* Seroconversion due to booster dose at a subject level is defined as a change from below the LOD to equal or above LOD, or for those who above the LOD  
451 pre-booster experienced at least a 4-fold rise in terms of nAbs.

452 **Table S4. Solicited and unsolicited adverse reactions that occurred within 28 days after booster**  
 453 **vaccination.**

Event Name	AWcorna (N=200)	CoronaVac (N=100)	P-Value
Severity	n(%)	n(%)	
<b>AE (Any)</b>	139(69.5)	20(20)	<b>&lt;0.0001</b>
Grade1	85(42.5)	12(12)	<b>&lt;0.0001</b>
Grade2	71(35.5)	6(6)	<b>&lt;0.0001</b>
Grade3	22(11)	3(3)	<b>0.0246</b>
Grade4	0(0)	0(0)	1
Grade5	0(0)	0(0)	1
≥Grade2	84(42)	9(9)	<b>&lt;0.0001</b>
≥Grade3	22(11)	3(3)	<b>0.0246</b>
<b>Solicited AE (Any)</b>	138(69)	20(20)	<b>&lt;0.0001</b>
Grade1	85(42.5)	12(12)	<b>&lt;0.0001</b>
Grade2	69(34.5)	6(6)	<b>&lt;0.0001</b>
Grade3	22(11)	3(3)	<b>0.0246</b>
Grade4	0(0)	0(0)	1
≥Grade2	83(41.5)	9(9)	<b>&lt;0.0001</b>
≥Grade3	22(11)	3(3)	<b>0.0246</b>
<b>Systemic (Any)</b>	131(65.5)	20(20)	<b>&lt;0.0001</b>
Grade1	73(36.5)	12(12)	<b>&lt;0.0001</b>
Grade2	67(33.5)	6(6)	<b>&lt;0.0001</b>
Grade3	20(10)	3(3)	<b>0.0372</b>
Grade4	0(0)	0(0)	1
≥Grade2	82(41)	9(9)	<b>&lt;0.0001</b>
≥Grade3	20(10)	3(3)	<b>0.0372</b>
<b>Fever (FDA Standard, Any)</b>	67(33.5)	4(4)	<b>&lt;0.0001</b>
Grade1	39(19.5)	2(2)	<b>&lt;0.0001</b>
Grade2	20(10)	2(2)	<b>0.0100</b>
Grade3	8(4)	0(0)	0.0555
Grade4	0(0)	0(0)	1
≥Grade2	28(14)	2(2)	<b>0.0008</b>
≥Grade3	8(4)	0(0)	0.0555

Diarrhea (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Nausea (Any)	5(2.5)	1(1)	0.6674
Grade1	4(2)	0(0)	0.3052
Grade2	1(0.5)	0(0)	1
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	1(0.5)	1(1)	1
≥Grade3	0(0)	1(1)	0.3333
Vomiting (Any)	5(2.5)	1(1)	0.6674
Grade1	5(2.5)	0(0)	0.1734
Grade2	0(0)	0(0)	1
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	1(1)	0.3333
≥Grade3	0(0)	1(1)	0.3333
Headache (Any)	52(26)	7(7)	<b>&lt;0.0001</b>
Grade1	11(5.5)	3(3)	0.3993
Grade2	41(20.5)	3(3)	<b>&lt;0.0001</b>
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	41(20.5)	4(4)	<b>&lt;0.0001</b>
≥Grade3	0(0)	1(1)	0.3333
Muscle Aches (Any)	15(7.5)	1(1)	<b>0.0255</b>
Grade1	5(2.5)	0(0)	0.1734
Grade2	9(4.5)	1(1)	0.1732
Grade3	1(0.5)	0(0)	1
Grade4	0(0)	0(0)	1

≥Grade2	10(5)	1(1)	0.1073
≥Grade3	1(0.5)	0(0)	1
Joint Pain (Any)	6(3)	1(1)	0.4310
Grade1	3(1.5)	0(0)	0.5533
Grade2	2(1)	1(1)	1
Grade3	1(0.5)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	3(1.5)	1(1)	1
≥Grade3	1(0.5)	0(0)	1
Chills (Any)	10(5)	1(1)	0.1073
Grade1	7(3.5)	1(1)	0.2765
Grade2	3(1.5)	0(0)	0.5533
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	3(1.5)	0(0)	0.5533
≥Grade3	0(0)	0(0)	1
Fatigue (Any)	4(2)	0(0)	0.3052
Grade1	2(1)	0(0)	0.5541
Grade2	1(0.5)	0(0)	1
Grade3	1(0.5)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	2(1)	0(0)	0.5541
≥Grade3	1(0.5)	0(0)	1
Rash (Not at Injection Site, Any)	0(0)	1(1)	0.3333
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	1(1)	0.3333
≥Grade3	0(0)	1(1)	0.3333
Hypersensitivity (Any)	1(0.5)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	1(0.5)	0(0)	1

Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	1(0.5)	0(0)	1
≥Grade3	0(0)	0(0)	1
Local AE (Any)	34(17)	2(2)	<b>&lt;0.0001</b>
Grade1	26(13)	2(2)	<b>0.0013</b>
Grade2	7(3.5)	0(0)	0.0998
Grade3	2(1)	0(0)	0.5541
Grade4	0(0)	0(0)	1
≥Grade2	9(4.5)	0(0)	<b>0.0319</b>
≥Grade3	2(1)	0(0)	0.5541
Pain at Injection Site (Any)	34(17)	2(2)	<b>&lt;0.0001</b>
Grade1	25(12.5)	2(2)	<b>0.0021</b>
Grade2	7(3.5)	0(0)	0.0998
Grade3	2(1)	0(0)	0.5541
Grade4	0(0)	0(0)	1
≥Grade2	9(4.5)	0(0)	<b>0.0319</b>
≥Grade3	2(1)	0(0)	0.5541
Induration (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Redness (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Rash (at Injection Site, Any)	0(0)	0(0)	1

Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Swelling (Any)	2(1)	0(0)	<b>0.5541</b>
Grade1	2(1)	0(0)	<b>0.5541</b>
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Itch (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Unsolicited AE (Any)	2(1)	1(1)	1
Grade1	0(0)	0(0)	1
Grade2	2(1)	0(0)	<b>0.5541</b>
Grade3	0(0)	1(1)	<b>0.3333</b>
Grade4	0(0)	0(0)	1
Grade5	0(0)	0(0)	1
≥Grade2	2(1)	1(1)	1
≥Grade3	0(0)	1(1)	<b>0.3333</b>

454 Data are n (%). n, number of participants; %, percentage of participants; any, all participants with any grade  
455 of adverse reactions. The analysis was based on the per-protocol population. *P* values shown in bold are  
456 <0.05.